公开(公告)号：US08105593B2

公开(公告)日：2012-01-31

申请号：US12793775

申请日：2010-06-04

申请人： Gene Kinney ,  William R. Strohl ,  Zhiqiang An

发明人： Gene Kinney ,  William R. Strohl ,  Zhiqiang An

IPC分类号： A61K39/395 ,  C07K16/18 ,  G01N33/53

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5058 ,  G01N2800/2814 ,  G01N2800/2821

摘要： The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

摘要翻译： 本发明涉及差异识别衍生的可扩散配体（也称为ADDL）的多维构象的抗体。 本发明的抗体可以区分阿尔茨海默病和对照人脑提取物，并且可用于检测ADDL和诊断阿尔茨海默病的方法。 本发明的抗体还阻断ADDL与神经元的结合，ADDL的组装和tau磷酸化，并且在预防和治疗与淀粉样蛋白的可溶性低聚物相关的疾病的方法中是有用的。 1-42。

公开(公告)号：US20100239597A1

公开(公告)日：2010-09-23

申请号：US12793775

申请日：2010-06-04

申请人： Gene Kinney ,  William R. Strohl ,  Zhiqiang An

发明人： Gene Kinney ,  William R. Strohl ,  Zhiqiang An

IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N5/00 ,  G01N33/53 ,  C07K14/47 ,  A61P25/28

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5058 ,  G01N2800/2814 ,  G01N2800/2821

摘要： The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

摘要翻译： 本发明涉及差异识别衍生的可扩散配体（也称为ADDL）的多维构象的抗体。 本发明的抗体可以区分阿尔茨海默病和对照人脑提取物，并且可用于检测ADDL和诊断阿尔茨海默病的方法。 本发明的抗体还阻断ADDL与神经元的结合，ADDL的组装和tau磷酸化，并且在预防和治疗与淀粉样蛋白的可溶性低聚物相关的疾病的方法中是有用的。 1-42。

公开(公告)号：US07731962B2

公开(公告)日：2010-06-08

申请号：US11581843

申请日：2006-10-17

申请人： Gene Kinney ,  William R. Strohl ,  Zhiqiang An

发明人： Gene Kinney ,  William R. Strohl ,  Zhiqiang An

IPC分类号： A61K39/395 ,  C07K16/18 ,  G01N33/53

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5058 ,  G01N2800/2814 ,  G01N2800/2821

摘要： The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

摘要翻译： 本发明涉及差异识别衍生的可扩散配体（也称为ADDL）的多维构象的抗体。 本发明的抗体可以区分阿尔茨海默病和对照人脑提取物，并且可用于检测ADDL和诊断阿尔茨海默病的方法。 本抗体还阻断ADDL与神经元的结合，ADDLS的组装和tau磷酸化，并且在用于预防和治疗与淀粉样蛋白的可溶性低聚物相关的疾病的方法中是有用的。 1-42。

公开(公告)号：US08420093B2

公开(公告)日：2013-04-16

申请号：US13361143

申请日：2012-01-30

申请人： Gene Kinney ,  William R. Strohl ,  Zhiqiang An

发明人： Gene Kinney ,  William R. Strohl ,  Zhiqiang An

IPC分类号： A61K39/395

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/92

摘要： The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

摘要翻译： 本发明涉及差异识别衍生的可扩散配体（也称为ADDL）的多维构象的抗体。 本发明的抗体可以区分阿尔茨海默病和对照人脑提取物，并且可用于检测ADDL和诊断阿尔茨海默病的方法。 本抗体还阻断ADDL与神经元的结合，ADDLS的组装和tau磷酸化，并且在用于预防和治疗与淀粉样蛋白的可溶性低聚物相关的疾病的方法中是有用的。 1-42。

公开(公告)号：US20070081998A1

公开(公告)日：2007-04-12

申请号：US11581843

申请日：2006-10-17

申请人： Gene Kinney ,  William Strohl ,  Zhiqiang An

发明人： Gene Kinney ,  William Strohl ,  Zhiqiang An

IPC分类号： A61K39/395 ,  C07K16/40

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5058 ,  G01N2800/2814 ,  G01N2800/2821

摘要： The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

摘要翻译： 本发明涉及差异地识别Abeta衍生的可扩散配体（也称为ADDL）的多维构象的抗体。 本发明的抗体可以区分阿尔茨海默病和对照人脑提取物，并且可用于检测ADDL和诊断阿尔茨海默病的方法。 本抗体还阻断ADDL与神经元的结合，ADDLS的组装和tau磷酸化，并且在用于预防和治疗与淀粉样蛋白β1-42的可溶性低聚物相关的疾病的方法中是有用的。

公开(公告)号：US20090098155A1

公开(公告)日：2009-04-16

申请号：US11919897

申请日：2006-05-01

申请人： Victor M. Garsky ,  Joseph G. Joyce ,  Paul M. Keller ,  Gene Kinney ,  Xiaoping Liang ,  John W. Shiver

发明人： Victor M. Garsky ,  Joseph G. Joyce ,  Paul M. Keller ,  Gene Kinney ,  Xiaoping Liang ,  John W. Shiver

IPC分类号： A61K39/385 ,  A61P31/12

CPC分类号： A61K39/0007 ,  A61K2039/6068 ,  A61K2039/6087 ,  A61K2039/6093 ,  A61K2039/64

摘要： The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.

摘要翻译： 本发明提供了用于治疗与患者的脑中的Aβ的淀粉样蛋白沉积相关的疾病的组合物和方法，例如阿尔茨海默氏病。 这种方法需要施用Abeta的免疫原性片段，缺乏T细胞表位，能够以Abeta抗体的形式诱导有益的免疫应答。 另一方面，Abeta的免疫原性片段能够提高血浆Abeta水平。 免疫原性片段包含Abeta的线性或多价肽。 药物组合物包含与可与佐剂一起施用的载体分子化学连接的免疫原性片段。

公开(公告)号：US07850973B2

公开(公告)日：2010-12-14

申请号：US11919897

申请日：2006-05-01

申请人： Victor M. Garsky ,  Joseph G. Joyce ,  Paul M. Keller ,  Gene Kinney ,  Xiaoping Liang ,  John W. Shiver

发明人： Victor M. Garsky ,  Joseph G. Joyce ,  Paul M. Keller ,  Gene Kinney ,  Xiaoping Liang ,  John W. Shiver

IPC分类号： A61K39/00 ,  A61K39/08 ,  A61K39/095 ,  A61K39/02 ,  A61K38/08 ,  A61K45/00 ,  A61K33/06

CPC分类号： A61K39/0007 ,  A61K2039/6068 ,  A61K2039/6087 ,  A61K2039/6093 ,  A61K2039/64

摘要： The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.

摘要翻译： 本发明提供了用于治疗与淀粉样蛋白沉积相关的疾病的组合物和方法。 在患者的脑中，如阿尔茨海默病。 这种方法需要施用能够以A和Bgr的抗体形式诱导有益的免疫应答的A＆bgr的免疫原性片段，缺少T细胞表位。 另一方面，A＆bgr的免疫原性片段 能够提升血浆A＆bgr; 水平。 免疫原性片段包含A和Bgr的线性或多价肽。 药物组合物包含与可与佐剂一起施用的载体分子化学连接的免疫原性片段。

公开(公告)号：US20230355729A1

公开(公告)日：2023-11-09

申请号：US18245532

申请日：2021-08-06

申请人： Robin BARBOUR ,  Gene KINNEY ,  Wagner ZAGO ,  OTHAIR PROTHENA LIMITED

发明人： Robin Barbour ,  Gene Kinney ,  Wagner Zago

IPC分类号： A61K39/00 ,  A61P25/28

CPC分类号： A61K39/0007 ,  A61P25/28 ,  A61K2039/6037 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55572

摘要： The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing alpha-synuclein and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and an alpha-synuclein peptide.

公开(公告)号：US20060166972A1

公开(公告)日：2006-07-27

申请号：US10564029

申请日：2004-07-07

申请人： P. Conn ,  Anthony DiLella ,  Gene Kinney ,  Michael Marino ,  Guy Seabrook ,  David Williams

发明人： P. Conn ,  Anthony DiLella ,  Gene Kinney ,  Michael Marino ,  Guy Seabrook ,  David Williams

IPC分类号： A61K31/5513 ,  A61K31/551 ,  A61K31/5415 ,  A61K31/553 ,  A61K31/198 ,  A61K31/445 ,  A61K31/48

CPC分类号： A61K31/35 ,  A61K31/198 ,  A61K31/445 ,  A61K31/48 ,  A61K31/5415 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/553

摘要： An mGluR4 receptor positive allosteric modulator is useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders such as Parkinson's disease, dyskinesia, tardive dyskinesia, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonian-ALS dementia complex, basal ganglia calcification, akinesia, akinetic-rigid syndrome, bradykinesia, dystonia, medication-induced parkinsonian, Gilles de la Tourette syndrome, Huntington's disease, tremor, chorea, myoclonus, tick disorder, and dystonia.

摘要翻译： mGluR4受体阳性变构调节剂单独使用或与精神安定药联合用于治疗或预防运动障碍如帕金森病，运动障碍，迟发性运动障碍，药物诱导的帕金森综合征，后脑卒中帕金森综合征，进行性核上性麻痹，多系统萎缩， 皮质基底膜变性，帕金森病ALS痴呆复合体，基底神经节钙化，运动不良，运动障碍，运动障碍，运动迟缓，肌张力障碍，药物诱导的帕金森病，Gilles de la Tourette综合征，亨廷顿病，震颤，舞蹈病，肌阵挛，蜱疾病和肌张力障碍。

公开(公告)号：US20230183304A1

公开(公告)日：2023-06-15

申请号：US17925813

申请日：2021-05-19

申请人： Robinoo BARBOUR ,  Gene KINNEY ,  Wagner ZAGO ,  Tarlochan S. NIJJAR ,  OTHAIR PROTHENA LIMITED

发明人： Robin Barbour ,  Gene Kinney ,  Wagner Zago ,  Tarlochan Nijjar

IPC分类号： C07K14/47 ,  A61P25/28 ,  A61K39/00 ,  A61K39/39 ,  A61P37/04

CPC分类号： C07K14/4711 ,  A61P25/28 ,  A61K39/0007 ,  A61K39/39 ,  A61P37/04 ,  A61K2039/55516 ,  A61K2039/55577 ,  A61K2039/55572 ,  A61K2039/55555 ,  C07K2319/00 ,  A61K2039/53 ,  A61K2039/55544 ,  A61K2039/545 ,  A61K2039/575 ,  A61K2039/6037

摘要： The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and a fau. peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or oilier diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or tan, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide.